Not all DTC patients with N positive disease deserve the attribution “high risk”. Contribution of the MSDS trial
Authors:
- Alexis VrachimisAVAlexis Vrachimis
- on behalf of the MSDS study groupOGon behalf of the MSDS study group
- 12 June 2015
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 112 (1) , 9-14
Abstract
Background and Objectives To investigate if patients with thyroid carcinoma having N1a disease are at the same risk with N1b using the collective of the well‐defined European prospective Multicentre Study Differentiated Thyroid Cancer (MSDS). Methods Overall (OS) and event free survival (EFS) were calculated. Cox multivariable regression analysis was performed in order to calculate Hazard ratios (HR). Results EFS was significantly decreased only in patients with N1b metastasis as compared to N0 patients and became worse when N1a was concomitantly affected. A superior survival in favor of N1a patients as compared to N1b patients with regard to EFS was also observed. The patients having N1a disease showed no differences in the EFS as compared to N0. OS did not differ significantly in any of the groups. There was an increased HR for events with regards to histology, T‐stage, tumor size, UICC stage and cervical lymph node metastasis. Tumor size showed a significantly increased risk for OS. Conclusions Patients with pT3b and pT4a tumors with N1b are of higher risk for relapse, albeit not affecting overall survival. Patients with N1a are of no higher risk. The risk stratification of these patients may be adapted accordingly. J. Surg. Oncol.Keywords
Funding Information
- the German Cancer Aid (70-2294, 10-8723)
This publication has 15 references indexed in Scilit:
- German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumorsLangenbeck's Archives of Surgery, 2013
- Peace of mind for patients with differentiated thyroid cancer?Nuklearmedizin-Nuclear Medicine, 2013
- Cervical lymph node metastasis and papillary thyroid carcinoma: Does the compartment involved affect survival? Experience from the SEER databaseJournal of Surgical Oncology, 2012
- Radioiodine for remnant ablation and therapy of metastatic diseaseNature Reviews Endocrinology, 2011
- Primary tumour size is a prognostic parameter in patients suffering from differentiated thyroid carcinoma with extrathyroidal growth: results of the MSDS trialEuropean Journal of Endocrinology, 2010
- Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancerNuklearmedizin-Nuclear Medicine, 2009
- Acute Toxicity of Adjuvant Radiotherapy in Locally Advanced Differentiated Thyroid CarcinomaStrahlentherapie und Onkologie, 2003
- A Population‐Based Analysis of Survival Factors in Differentiated and Medullary Thyroid CarcinomaOtolaryngology–Head and Neck Surgery, 2003
- Pattern of Nodal Metastasis for Primary and Reoperative Thyroid CancerWorld Journal of Surgery, 2001
- Standardizing Neck Dissection Terminology: Official Report of the Academy's Committee for Head and Neck Surgery and OncologyJAMA Otolaryngology–Head & Neck Surgery, 1991